Stuart Krauss, MD
Hematology & Oncology · Chicago, ILNPI 1336166875
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,640 of the $16,998 with a category attached, or 62.6%. It is spread thinly across 41 manufacturers, the largest accounting for just 13.0%. Reporting peaked in 2019 at $5,104 and has fallen 98.6% since, to $69 in 2024.
Across 492 payments — averaging $34.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Johnson & Johnson$2K
- Exelixis Inc.$1K
- R-pharm US LLC$1K
- Novartis$1K
- E.r. Squibb & Sons, L.L.C.$1K
- plus $8K from 35 others
Across 3 payments — averaging $1041.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$3K
What the payments were for
- Consulting fees$4,49026%
- Speaking & faculty fees$1,4709%
- Travel & lodging$1121%
- Food & beverage$10,64063%
- Education$2872%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 15 | $2,213 |
| Johnson & Johnson | 17 | $1,954 |
| Exelixis Inc. | 1 | $1,470 |
| R-pharm US LLC | 3 | $1,367 |
| Novartis | 70 | $1,270 |
| E.r. Squibb & Sons, L.L.C. | 58 | $1,197 |
| AstraZeneca | 22 | $1,005 |
| Genentech USA, Inc. | 41 | $814 |
| Pfizer | 38 | $756 |
| Seagen Inc. | 26 | $644 |
| Merck | 28 | $475 |
| Daiichi Sankyo Inc. | 19 | $374 |
| Bristol Myers Squibb | 12 | $322 |
| ADC Therapeutics America, Inc. | 5 | $307 |
| Amgen | 13 | $304 |
| Astellas Pharma US Inc | 11 | $255 |
| AbbVie | 10 | $224 |
| Pharmacyclics LLC, An Abbvie Company | 12 | $222 |
| Gilead(2 entities) | 12 | $220 |
| EMD Serono, Inc. | 14 | $216 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $178 |
| Sanofi | 4 | $167 |
| Eisai Inc. | 9 | $165 |
| Servier Pharmaceuticals LLC | 7 | $152 |
| Bayer | 8 | $148 |
| Lilly USA, LLC | 5 | $109 |
| Adaptive Biotechnologies Corporation | 3 | $93 |
| Jazz Pharmaceuticals Inc. | 2 | $73 |
| CTI Biopharma Corp. | 2 | $49 |
| G1 Therapeutics, Inc. | 3 | $42 |
| Puma Biotechnology, Inc. | 2 | $41 |
| Dova Pharmaceuticals | 2 | $31 |
| EUSA Pharma (US) LLC | 1 | $24 |
| Immunomedics, Inc. | 1 | $20 |
| Incyte Corporation | 1 | $17 |
| Taiho Oncology, Inc. | 1 | $15 |
| Mylan Institutional Inc. | 1 | $14 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $14 |
| Tersera Therapeutics LLC | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
| AMAG Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,998 in reported general payments places this provider in the 75th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Chicago
- Michael BishopChicago$974K
- Jamile ShammoChicago$910K
- Young Kwang ChaeChicago$563K
- Irfan MirzaChicago$544K
- Marina GarassinoChicago$397K
- Chih-Yi LiaoChicago$317K
- Rita NandaChicago$286K
- Shuo MaChicago$280K
- Santosh SarafChicago$275K
- Peter RiedellChicago$273K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.